|
 |
fluticasone propionate salmeterolThis page contains recent news articles, when available, and an overview of fluticasone propionate salmeterol but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The study was supported by GlaxoSmithKline of Research Triangle Park, North Carolina, which markets fluticasone propionate/salmeterol as Advair Diskus. news Stories Advair(R) (Fluticasone Propionate/Salmeterol) HFA Inhalation Aerosol ... - Oct 19, 2006 RESEARCH TRIANGLE PARK, NC -- October 19, 2006 -- Advair HFA Inhalation Aerosol, a new formulation combining fluticasone propionate and salmeterol in a ... DG News Seretide Accuhaler DPI - Fluticasone propionate, Salmeterol xinafoate... - Jan 2, 2008 Seretide accuhaler is used for maintenance treatment of asthma, a disease of the airways and lungs characterised by shortness of breath, wheezing, ... Virtual Medical Centre - The Virtual Medical Centre GSK Receives Extended Licence Indication For Seretide In Europe … - Jul 16, 2007 GSK announced today that it has been granted a licence extension in Europefor Seretideâ„¢ 50/500µg(salmeterol/fluticasone propionate) for use in a broader ... Medical News Today - Medical News Today (press release) … on dose; Seretide (fluticasone propionate/salmeterol xinafoate) is... - May 11, 2006 SERETIDE metered dose inhaler (MDI) is now manufactured with a counter, which helps patients know how many doses they have left, making it the first MDI in ... Pay-Per-View - Pharmacy News - Factiva, from Dow Jones COPD - Positive Results Of Seretide Survival Study - Mar 29, 2006 GlaxoSmithKline plc announces preliminary results from the TORCH study (TOwards a Revolution in COPD Health) which show a 17% relative reduction in ... Medical News Today - Medical News Today (press release) Two asthma drugs' efficacy compared.(Pulmonary Medicine) | Article... - Oct 15, 2005 HFA Inhalation Aerosol (fluticasone propionate and salmeterol) for long ... 115 mcg, and 230 mcg fluticasone propionate each combined with 21 mcg ... ... Pay-Per-View - Family Practice News - HighBeam Research No Added Benefit When Montelukast Added to Fluticasone/Salmeterol in ... - May 23, 2008 By Marvin Ross. TORONTO -- May 23, 2008 -- Patients with both asthma and allergic rhinitis experience significantly better lung function when they are ... DG News GSK Announces Positive Results of Seretide Survival Study In Patients... - Mar 28, 2006 PHILADELPHIA, March 28 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc announces preliminary results from the TORCH study (TOwards a Revolution in COPD ... Free with registration - PR Newswire - AccessMyLibrary.com Article: Advair HFA, Omnitrope.(New & Approved) - Pediatric News | … - Aug 1, 2006 Advair HFA, Omnitrope.(New & Approved) ... find Pediatric News articles. Advair HFA (fluticasone propionate/salmeterol inhalation aerosol, GlaxoSmithKline) ... Pay-Per-View - Pediatric News - HighBeam Research … with a step down daily dose of fluticasone propionate/salmeterol - May 16, 2006 2006 MAY 16 - (NewsRx.com) -- In patients who have controlled their asthma with fluticasone propionate/salmeterol (FSC) 250/50 microg twice daily, ... Pay-Per-View - Medical Devices & Surgical Technology... - Factiva, from Dow Jones Treating comorbidities may not benefit asthma.(Pulmonary Medicine) | ... - Apr 1, 2008 Treating comorbidities may not benefit asthma.(Pulmonary Medicine) ... find Family Practice News articles. KEYSTONE, COLO. -- Optimal treatment of allergic ... Pay-Per-View - Family Practice News - HighBeam Research FDA panel recommends warning on salmeterol. - Dec 10, 2007 A US Food and Drug Adminstration advisory panel has recommended that three popular asthma drugs should get label warnings about their potential risk to ... $4.95 - Pharma Marketletter - ECNext Article: Advair HFA, omnitrope.(drug approval) - Family Practice News... - Aug 15, 2006 Advair HFA, omnitrope.(drug approval) ... find Family Practice News articles. Advair HFA (fluticasone propionate/sal meterol inhalation aerosol, ... Pay-Per-View - Family Practice News - HighBeam Research Intranasal Ciclesonide Added to High-Dose Inhaled Fluticasone Does... - Mar 2, 2007 By Paula Moyer. SAN DIEGO, CA -- March 2, 2007 -- Intranasal ciclesonide (Alvesco) along with high-dose inhaled fluticasone combined with salmeterol ... DG News Article: FDA panel supports two asthma bronchodilators.(News) - … - Sep 1, 2005 FDA panel supports two asthma bronchodilators.(News) ... find Pediatric News articles. GAITHERSBURG, MD. -- The two long-acting inhaled [beta.sub.2]-agonist ... Pay-Per-View - Pediatric News - HighBeam Research Press Release: New Data Show Advair(R) Reduces Asthma-Related … - Mar 15, 2008 New Data Show Advair(R) Reduces Asthma-Related Hospitalization and Emergency Department Visits. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Step-down therapy feasible for stabilized asthma.(Pulmonary Medicine)(... - Jul 15, 2006 Step-down therapy feasible for stabilized asthma.(Pulmonary Medicine)(Drug overview) ... find Family Practice News articles. Pay-Per-View - Family Practice News - HighBeam Research Patients Satisfied With Fluticasone/Salmeterol Treatment by Diskus... - Nov 4, 2005 By Ed Susman. MONTREAL, CANADA -- November 4, 2005 -- Patients reported a high degree of satisfaction after 2 months of using a new treatment for chronic ... DG News AAAAI: Albuterol Said to Work Faster than Combination Agents for … - Mar 20, 2008 By John Gever, Staff Writer, MedPage Today. PHILADELPHIA, March 20 -- Inhaled albuterol (Proventil) brought faster increases in asthma patients' lung ... MedPage Today Press Release: GSK Announces Positive Results of Seretide Survival … - Mar 28, 2006 GSK Announces Positive Results of Seretide Survival Study In Patients With Chronic Obstructive Pulmonary Disease (COPD). from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids... - Jul 1, 2008 Background: Recent analyses have suggested an increased risk for serious asthma-related adverse events in patients receiving long-acting β-agonists. ... Annals of Internal Medicine Drug combination reduces mortality from chronic obstructive pulmonary... - Sep 5, 2006 Medication reduces risk of dying from chronic obstructive pulmonary disease, according to the first study of its kind. Chronic obstructive pulmonary disease ... HealthandAge.com Advair Diskus, Advair HFA, Brovana, Foradil, Serevent Diskus, and … - Nov 18, 2005 On November 18, 2005, FDA alerted health care professionals and patients that several long-acting bronchodilator medicines have been associated with ... FierceBiotech Fast- Plus Long-Acting Beta Agonist Improves Asthma Maintenance … - Mar 24, 2008 By Em Brown. PHILADELPHIA -- March 24, 2008 -- A study presented here at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting shows ... DG News Control of Airway Inflammation Maintained at a Lower Steroid Dose... - Sep 19, 2006 This study of 88 patients, aged 18 years and over, was presented at a recent meeting of the American Thoracic Society and was an editor's choice in this ... Medscape FDA decision means Serevent, Advair, and Foradil to remain on market - Sep 1, 2005 A Food and Drug Administration advisory committee recommended in July that Serevent (salmeterol), Advair (fluticasone propionate/salmeterol), ... Contemporary Pediatrics Finding multiple target optimal intervention in disease-related... - Nov 4, 2008 Correspondence to: Luhua Lai 1, 2 Beijing National Laboratory for Molecular Sciences, State Key Laboratory for Structural Chemistry of Unstable and Stable ... Nature.com Advair's Growth Could Be Hurt by FDA Labeling Proposal, Analysts Say - Nov 22, 2005 Future growth opportunity for GlaxoSmithKline's (GSK) best-selling asthma treatment Advair could be curtailed if the firm places restrictions on the drug's ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones The GOAL Study Designed to Favor a Long-Acting [Beta]^Sub 2^- Agonist... - May 12, 2005 Bateman and colleagues (1) have demonstrated that a fluticasone propionate/salmeterol combination (FP/SM) conferred superiority on guideline-derived asthma ... RedOrbit USA policy: FDA divided on safety of Serevent and Foradil - Dec 10, 2008 The US Food and Drug Administration is divided on whether long-acting beta-agonists should continue to be used for the treatment of asthma in adults and ... $34.00 - EIU Country Analysis - Alacra Store Lower Avandia Rxing and generics take a toll on GlaxoSmithKline's... - Oct 29, 2007 Global number two drugmaker GlaxoSmithKline has disappointed investors, posting sales for the third quarter of 2007 that were below consensus expectations, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Factiva Search - May 17, 2006 Factiva Search 2.0. BETA. Factiva iWorksâ„¢ offers Factiva's exclusive collection of world-class information indexed and optimized for business use. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Asthma Drugs Should Remain on Market, But Foradil Needs Black Box, … - Jul 15, 2005 An FDA advisory committee has recommended that three asthma drugs remain on the market despite concerns the products might cause severe asthma attacks in a ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones Asthma Patients Should Not Take Drug Holiday From Maintenance … - Mar 18, 2008 March 18, 2008 (Philadelphia) — Not taking a summer break from maintenance therapy with fluticasone propionate/salmeterol (Advair, GlaxoSmithKline) ... Medscape EBSCOhost Connection: CLINICAL CLIPS / EVIDENCE-BASED … - May 1, 2006 Patient Care for the Nurse Practitioner: Several case studies of evidence-based medical research are presented. These include "Asthma Control Can Be ... Subscription - Patient Care for the Nurse Practitioner - EBSCO Publishing GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite... - Apr 30, 2007 GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure. UK drug major GlaxoSmithKline says that its first-quarter 2007 ... $9.94 - Pharma Marketletter - Alacra Store GlaxoSmithKline sees flattish 2nd-qtr results, but sales helped by... - Jul 30, 2007 GlaxoSmithKline sees flattish 2nd-qtr results, but sales helped by Advair. Global number two drugmaker GlaxoSmithKline beat analysts' consensus forecasts, ... $9.94 - Pharma Marketletter - Alacra Store Stock Commentary - Europe - week to Nov 21.(Brief Article) - Nov 28, 2005 EUROPEAN: bourses started the reporting week to November 21 in negative mode, but picked up significantly as the reporting period moved forward, ... $4.95 - Pharma Marketletter - ECNext Federal Register 2007 - 72 FR 13500 Pulmonary-Allergy Drugs Advisory ... - Mar 22, 2007 72 FR 13500 Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting March 22, 2007 AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ... Pay-Per-View - Federal Register 2007 - Loislaw Misleading Clinical Study May Bolster FACT Act, Consumer Group Claims - Oct 10, 2005 A major drug manufacturer's alleged manipulation of a clinical study may bolster the prospects of Senate legislation that would require drugmakers to submit ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones AOTM issues first conditional recommendations - Sep 24, 2008 The Medical Technologies' Assessment Agency (AOTM) has issued six new recommendations for drug reimbursement. Most are so-called conditional positive ... Polish Market Innovata secures L25M Duohaler asthma deal.(Innovata Biomed) - Dec 19, 2005 Nottingham, UK-headquartered pulmonary drug-delivery specialist Innovata has signed a second agreement centered on its its novel Duohaler (C200) inhalation ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Step-down asthma therapy.(Brief article) - May 1, 2006 Bateman ED, Jacques L, Goldfrad C, et al. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. ... Free with registration - Patient Care for the Nurse Practitioner - AccessMyLibrary.com GlaxoSmithKline pleases with 3rd-qtr results and raised full-year … - Nov 7, 2005 The world's second-largest pharmaceutical group, GlaxoSmithKline, has reported a 16% increase (at constant exchange rates) in pretax profit for the third ... Free with registration - Pharma Marketletter - AccessMyLibrary.com UK pharma: Generics lead to 13% US sales decline for GSK - Oct 23, 2008 GlaxoSmithKline's third-quarter 2008 profit fell 21.6% year-on-year to L1.03 billion ($1.76 billion) as generic competition eroded sales of its older ... $34.00 - EIU Country Analysis - Alacra Store Drug firms show innovation in dealing with patent expiry. - Jul 31, 2006 Drug firms show innovation in dealing with patent expiry. Four of the USA's top 10 best-selling prescription drugs face patent expiry this year, providing, ... $9.94 - Pharma Marketletter - Alacra Store A reality check on emerging markets. - Jul 1, 2008 A reality check on emerging markets. Emerging markets, particularly the "BRIC" countries (Brazil, Russia, India, and China), are playing an increasingly ... $20.00 - Pharmaceutical Technology - Alacra Store Turnaround for GSK as generic woes abate, future looks bright with... - Feb 21, 2005 UK drug major GlaxoSmithKline seems to be clawing back from the onslaught of generic competition which some of its blockbuster drugs have faced during the ... $4.95 - Pharma Marketletter - ECNext Studies Showed Lack of Asthma Control Leads to Increased Emergency … - May 24, 2006 SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- Two recent retrospective claims analyses in a managed care setting included case records for 3998 asthma ... Free with registration - PR Newswire - AccessMyLibrary.com Management of COPD Associated With Chronic Bronchitis: Abstract - Mar 29, 2006 Context: Chronic obstructive pulmonary disease (COPD) is recognized as a major healthcare problem in the United States and around the world. ... Medscape GlaxoSmithKline's 7% sales growth and 18% EPS rise in line with … - Feb 13, 2006 The world's second-largest drugmaker by sales, GlaxoSmithKline, has posted a strong set of results for 2005, showing turnover up 7% at L21.66 billion ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Strong data for GSK's Seretide/Advair in COPD.(GlaxoSmithKline PLC)( … - Apr 3, 2006 UK drug major GlaxoSmithKline says that topline results from a study of its drug Seretide/Advair (fluticasone propionate/salmeterol) in Chronic Obstructive ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Regular treatment can enable asthma patients to lead normal life:... - Apr 30, 2006 Karachi, April 30 (PPI): A sustained regular treatment can enable asthma patients (even with severe asthma) to lead a completely normal, symptom-free life, ... Free with registration - PPI - Pakistan Press International - AccessMyLibrary.com Studies Showed Lack of Asthma Control Leads to Increased Emergency … - May 30, 2006 SAN DIEGO, CA -- May 30, 2006 -- Two recent retrospective claims analyses in a managed care setting included case records for 3998 asthma patients and ... DG News GSK's 1st-qtr 2008 EPS drops 5% on Avandia sales slump and generic … - Apr 28, 2008 GSK's 1st-qtr 2008 EPS drops 5% on Avandia sales slump and generic competition. UK drug major GlaxoSmithKline's first-quarter 2008 earnings per share fell ... $9.94 - Pharma Marketletter - Alacra Store GlaxoSmithKline sees 1st- qtr EPS rise 19%, as generic woes diminish. - May 2, 2005 UK-based GlaxoSmithKline, the world's second-largest drugmaker, has posted a strong set of results for the first quarter of 2005, with pretax profits up 18% ... $4.95 - Pharma Marketletter - ECNext GSK beats expectations in the 2nd qtr, but still slightly down on... - Jul 28, 2008 GSK beats expectations in the 2nd qtr, but still slightly down on last year. UK-based drug major GlaxoSmithKline beat consensus estimates, despite reporting ... $9.94 - Pharma Marketletter - Alacra Store GlaxoSmithKline sees 10% EPS rise on 6% sales growth.(markets)(Brief ... - Aug 1, 2005 GlaxoSmithKline, the world's second largest pharmaceutical company, posted a 6% rise in second-quarter 2005 turnover at L5.25 billion ($9.17 billion), ... $4.95 - Pharma Marketletter - ECNext AstraZeneca welcomes TORCH trial results - Mar 30, 2006 Anglo-Swedish drug major Astra Zeneca has said that it "welcomes" the preliminary results of the TORCH (TOwards a Revolution in COPD Health) study1, ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones AstraZeneca welcomes TORCH trial results.(TOwards a Revolution in … - Apr 3, 2006 Anglo-Swedish drug major Astra Zeneca has said that it "welcomes" the preliminary results of the TORCH (TOwards a Revolution in COPD Health) study1, ... $4.95 - Pharma Marketletter - ECNext Press Release: Study Compares Bronchodilatory Effects of SYMBICORT( … - Mar 18, 2008 Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Patent expiry for 2008 provides generic opportunity. - Jan 14, 2008 Patent expiry for 2008 provides generic opportunity. Seven blockbuster drugs face patent expiry in the USA during the course of 2008, according to IMS ... $9.94 - Pharma Marketletter - Alacra Store Press Release: Studies Showed Lack of Asthma Control Leads to … - May 24, 2006 Studies Showed Lack of Asthma Control Leads to Increased Emergency Room Visits and Hospitalization. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research GSK sees 2008 EPS fall; posts 2007 results. - Feb 18, 2008 GSK sees 2008 EPS fall; posts 2007 results. UK headquartered GlaxoSmithKline, the world's second largest drugmaker by sales, has disappointed investors with ... $9.94 - Pharma Marketletter - Alacra Store Factiva Search - Mar 30, 2006 Factiva Search 2.0. BETA. Factiva iWorksâ„¢ offers Factiva's exclusive collection of world-class information indexed and optimized for business use. ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones GSK's 3rd-qtr 2008 profit down 21.6% as generics lead to 13% US sales... - Oct 27, 2008 GSK's 3rd-qtr 2008 profit down 21.6% as generics lead to 13% US sales decline. GlaxoSmithKline's third-quarter 2008 profit fell 21.6% year-on-year to L1.03 ... $9.94 - Pharma Marketletter - Alacra Store GSK EPS rises 10% on 6% sales growth.(GlaxoSmithKline PLC earnings … - Aug 8, 2005 Despite problems at its Puerto Rico manufacturing plant that caused disruption of supplies of two of its leading products, Paxil/Seroxat (paroxetine) and ... $4.95 - Pharma Marketletter - ECNext КомбинированнаÑ? терапиÑ? больных бронхиальной аÑ?тмой более Ñ?? - Nov 17, 2006 Ð?а ежегодной конференции Ð?мериканÑ?кого колледжа аллергии, аÑ?тмы и иммунологии (9 — 15 ноÑ?брÑ? 2006 г., ФиладельфиÑ?, СШÐ?) компаниÑ? GlaxoSmithKline предÑ?тавила ... ФармацевтичеÑ?кий веÑ?тник |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |